PapersFlow Research Brief
Health Systems, Economic Evaluations, Quality of Life
Research Guide
What is Health Systems, Economic Evaluations, Quality of Life?
Health Systems, Economic Evaluations, Quality of Life is the research area that measures how healthcare interventions affect health-related quality of life and uses those measurements in economic evaluations (for example, cost-effectiveness analysis using QALYs) to inform health system decisions.
This topic cluster comprises 182,563 works focused on economic evaluation methods and preference-based quality-of-life measurement used in health technology assessment and related decision processes. Evidence synthesis and appraisal methods are central in this literature, including random-effects meta-analysis (DerSimonian and Laird (1986) in "Meta-analysis in clinical trials") and standardized reporting for systematic reviews (Moher et al. (2009) in "Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement"). Trial validity assessment frameworks commonly used to support economic evaluations include the Cochrane risk-of-bias approach (Higgins et al. (2011) in "The Cochrane Collaboration's tool for assessing risk of bias in randomised trials") and its revision (Sterne et al. (2019) in "RoB 2: a revised tool for assessing risk of bias in randomised trials").
Topic Hierarchy
Research Sub-Topics
EQ-5D Utility Valuation
Researchers develop and validate EQ-5D-based preference weights using time trade-off and discrete choice experiments across populations and countries. Studies focus on mapping algorithms between EQ-5D and disease-specific measures for economic evaluations.
SF-36 Health Survey Validation
This subfield validates the SF-36 questionnaire for utility elicitation, profile-based scoring, and responsiveness in clinical trials across chronic conditions. Researchers compare SF-6D utility algorithms with direct preference methods.
Quality-Adjusted Life Years Modeling
Studies advance QALY computation methods, including extrapolation techniques, age-weighting adjustments, and handling of missing data in Markov models for cost-utility analysis. Research addresses capability-based alternatives to standard QALYs.
Health Technology Assessment Methods
Researchers refine HTA methodologies for economic evaluation, including probabilistic sensitivity analysis, value of information, and multi-criteria decision analysis beyond cost-effectiveness ratios. Focus includes real-world evidence integration.
Preference-Based Health Measures
This area develops novel instruments like PROMIS preference scoring and vignette-based valuations, comparing them to EQ-5D/SF-36 in capturing patient preferences for economic studies. Research explores discrete choice experiments for utility elicitation.
Why It Matters
Health systems often allocate finite budgets across competing interventions, so economic evaluations that incorporate quality of life can affect which services are funded and for whom. A concrete example of real-world resource allocation pressure appears in U.S. rural health policy: the news item "Breaking Down Trump's $50 Billion Rural Health Fund" (2026) reports a $50 billion Rural Health Transformation Program, and "Michigan awarded more than $173 million in federal ..." (2025) reports $173,128,201 awarded to Michigan for FY 2026 under that program; such large funding decisions create demand for transparent evidence syntheses and credible assessments of benefits that include patient-relevant outcomes. Methods that improve the trustworthiness and usability of evidence—such as PRISMA reporting (Moher et al. (2009) in "Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement"), scoping review guidance (Tricco et al. (2018) in "PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation"), and structured risk-of-bias assessment (Higgins et al. (2011) in "The Cochrane Collaboration's tool for assessing risk of bias in randomised trials"; Sterne et al. (2019) in "RoB 2: a revised tool for assessing risk of bias in randomised trials")—directly shape what evidence is considered reliable enough to support coverage, reimbursement, and program design decisions.
Reading Guide
Where to Start
Start with Moher et al. (2009), "Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement", because economic evaluations depend on transparent, reproducible evidence identification and synthesis, and PRISMA provides a common structure for documenting that process.
Key Papers Explained
DerSimonian and Laird (1986) in "Meta-analysis in clinical trials" provides a foundational synthesis method often used to combine effect estimates across studies. Moher et al. (2009) in "Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement" and Tricco et al. (2018) in "PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation" address how to report the evidence-identification and evidence-mapping steps that precede and justify quantitative synthesis. Higgins et al. (2011) in "The Cochrane Collaboration's tool for assessing risk of bias in randomised trials" and Sterne et al. (2019) in "RoB 2: a revised tool for assessing risk of bias in randomised trials" provide structured ways to judge internal validity of trials whose results feed meta-analyses and, downstream, economic models; Guyatt et al. (2008) in "GRADE: an emerging consensus on rating quality of evidence and strength of recommendations" then connects those judgments to overall certainty and recommendation strength.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
For advanced work, focus on workflows that jointly improve transparency (PRISMA/PRISMA-ScR), internal-validity assessment (risk-of-bias tools), and decision-facing communication (GRADE) so that economic evaluations used in policy contexts can be audited and updated. The presence of large, explicitly quantified funding allocations in recent rural health policy reporting ("Breaking Down Trump's $50 Billion Rural Health Fund" (2026); "Michigan awarded more than $173 million in federal ..." (2025)) underscores the practical need for evidence packages that are both methodologically rigorous and clearly documented.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Meta-analysis in clinical trials | 1986 | Controlled Clinical Tr... | 38.3K | ✕ |
| 2 | Preferred Reporting Items for Systematic Reviews and Meta-Anal... | 2009 | Annals of Internal Med... | 37.2K | ✕ |
| 3 | PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist a... | 2018 | Annals of Internal Med... | 35.3K | ✕ |
| 4 | The Cochrane Collaboration's tool for assessing risk of bias i... | 2011 | BMJ | 32.7K | ✓ |
| 5 | RoB 2: a revised tool for assessing risk of bias in randomised... | 2019 | BMJ | 27.1K | ✓ |
| 6 | The Montreal Cognitive Assessment, MoCA: A Brief Screening Too... | 2005 | Journal of the America... | 23.9K | ✕ |
| 7 | Frailty in Older Adults: Evidence for a Phenotype | 2001 | The Journals of Geront... | 23.3K | ✓ |
| 8 | GRADE: an emerging consensus on rating quality of evidence and... | 2008 | BMJ | 20.4K | ✓ |
| 9 | Preferred Reporting Items for Systematic Reviews and Meta-Anal... | 2009 | Journal of Clinical Ep... | 19.5K | ✓ |
| 10 | Assessing the quality of reports of randomized clinical trials... | 1996 | Controlled Clinical Tr... | 17.6K | ✕ |
In the News
Rural Health Transformation (RHT) Program
* Application instructions to apply for RHT Program funding will be included in the NOFO and released on grants.gov by mid-September * CMS will engage with States in the open application period to ...
Breaking Down Trump's $50 Billion Rural Health Fund
Just before New Year’s, the Trump administration announced how much money each state would get from the $50 billion Rural Health Transformation Program.
Michigan awarded more than $173 million in federal ...
LANSING, Mich. – This week, the Michigan Department of Health and Human Services (MDHHS) was awarded $173,128,201 for FY 2026 by the Centers for Medicare & Medicaid Services under the Rural Health ...
Health economics
## Health economics All healthcare systems must make tough choices about the interventions and treatments they provide. With limited resources, decisions must be made about the most effective inter...
PBAC Guidelines | Section 3 Economic evaluation
In Section 3, present an economic evaluation of substituting the proposed medicine for the main comparator in the context of the listing requested. Information requests
Code & Tools
## Repository files navigation # ready4 ## Develop and Use Modular Health Economic Models
`darthtools` is an R package that contains tools developed by the Decision Analysis in R for\ Technologies in Health (DARTH) workgroup to construct...
`hesim` is a modular and computationally efficient R package for health economic simulation modeling and decision analysis that provides a general ...
Markov Models for Health Economic Evaluations. An implementation of the modelling and reporting features described in reference textbooks and guide...
clinical and economic evaluation of health care. Developed by the EuroQol group, the instrument consists of two components: health state descriptio...
Recent Preprints
Guide for authors - Value in Health Regional Issues
**Economic Evaluations**
Journal of Health Economics and Outcomes Research
Powered by Scholastica , the modern academic journal management system
Aligning Indigenous and Western Concepts of Health ...
foundational tools used to quantify the relative importance of different health states. Derived from general population preferences, these value sets assign weights to health states—typically asses...
(PDF) The concept of quality of life
specific medical procedures. By assessing QOL we gain valuable information about patients’ health status, including its psychosocial aspects, and the effectiveness of our therapeutic intervention...
Deriving monetary value of quality-adjusted life years ...
To address the recent rise in healthcare expenditure due to an aging population, the rational allocation and efficient use of resources, based on scientific evidence, have become indispensable. Thi...
Latest Developments
Recent developments in health systems, economic evaluations, and quality of life research as of February 2026 highlight ongoing shifts toward value-based care, technological integration, and improved measurement tools; key insights include the stabilization of health care delivery amid persistent pressures, the increasing importance of health-related quality of life instruments like EuroQol, and strategic adaptations by providers and payers to enhance resilience and efficiency (AHA, Deloitte, ICER).
Sources
Frequently Asked Questions
What methods are commonly used to synthesize evidence for parameters used in health economic evaluations?
DerSimonian and Laird (1986) in "Meta-analysis in clinical trials" described a widely used random-effects meta-analysis approach for combining results across studies when effects vary between studies. Such meta-analytic pooling is frequently used to inform effect sizes, event rates, and other inputs for decision models used in economic evaluations.
How should systematic reviews that inform health technology assessment be reported?
Moher et al. (2009) in "Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement" provided a standardized reporting framework intended to improve transparency and completeness in systematic reviews and meta-analyses. Transparent reporting helps readers assess whether the evidence base supporting an economic evaluation is comprehensive and reproducible.
How do researchers map broad evidence bases before conducting full economic evaluations or systematic reviews?
Tricco et al. (2018) in "PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation" outlined reporting guidance for scoping reviews designed to map evidence, clarify concepts, and identify knowledge gaps. Scoping reviews can be used to inventory outcome measures, populations, and interventions before selecting inputs and comparators for an economic evaluation.
How is risk of bias assessed in randomized trials that provide clinical-effectiveness inputs for economic evaluations?
Higgins et al. (2011) in "The Cochrane Collaboration's tool for assessing risk of bias in randomised trials" described a structured approach to evaluating bias domains in randomized trials. Sterne et al. (2019) in "RoB 2: a revised tool for assessing risk of bias in randomised trials" presented a revised version intended for contemporary trial designs and reporting.
Which frameworks are used to rate the quality of evidence and strength of recommendations that may accompany economic evidence?
Guyatt et al. (2008) in "GRADE: an emerging consensus on rating quality of evidence and strength of recommendations" described a system for rating evidence certainty and recommendation strength. Such ratings are often used alongside economic results to communicate how much confidence decision-makers should place in estimated benefits and trade-offs.
Which trial-reporting features have been debated as markers of study quality in evidence used for economic evaluations?
Jadad et al. (1996) in "Assessing the quality of reports of randomized clinical trials: Is blinding necessary?" examined whether blinding should be considered necessary when judging the quality of randomized trial reports. This debate matters because judgments about trial quality can influence which studies are included or down-weighted when estimating effectiveness inputs for economic models.
Open Research Questions
- ? How should evidence-synthesis pipelines for economic evaluations integrate random-effects meta-analysis (DerSimonian and Laird (1986) in "Meta-analysis in clinical trials") with structured risk-of-bias judgments (Higgins et al. (2011); Sterne et al. (2019)) when study results are heterogeneous?
- ? Which reporting elements from "Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement" (Moher et al., 2009) and "PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation" (Tricco et al., 2018) most improve reproducibility of evidence bases specifically assembled for cost-effectiveness models?
- ? How should GRADE certainty ratings (Guyatt et al. (2008) in "GRADE: an emerging consensus on rating quality of evidence and strength of recommendations") be operationally propagated into uncertainty analysis when economic conclusions depend on low- or very-low-certainty clinical evidence?
- ? When trial reports are incomplete, which aspects of reporting quality discussed by Jadad et al. (1996) in "Assessing the quality of reports of randomized clinical trials: Is blinding necessary?" most strongly affect downstream economic decisions, and how should analysts respond?
- ? How can scoping-review mapping (Tricco et al., 2018) be used to systematically identify gaps in quality-of-life measurement that limit the interpretability of health-system funding decisions like those described in "Breaking Down Trump's $50 Billion Rural Health Fund" (2026)?
Recent Trends
The scale of the literature itself—182,563 works in this cluster—indicates sustained, high-volume activity around economic evaluation and quality-of-life evidence used for health system decisions.
Methodological consolidation is visible in the continued centrality of standardized reporting and appraisal tools: PRISMA (Moher et al., 2009), PRISMA-ScR (Tricco et al., 2018), and structured risk-of-bias assessment (Higgins et al., 2011; Sterne et al., 2019) form a commonly cited backbone for building evidence bases that can support decision models.
In parallel, recent health policy reporting highlights large, explicitly quantified funding decisions—$50 billion nationally ("Breaking Down Trump's $50 Billion Rural Health Fund" ) and $173,128,201 awarded to Michigan for FY 2026 ("Michigan awarded more than $173 million in federal ..." (2025))—that increase demand for economic evaluations that credibly incorporate patient-relevant outcomes such as quality of life.
2026Research Health Systems, Economic Evaluations, Quality of Life with AI
PapersFlow provides specialized AI tools for Economics, Econometrics and Finance researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Systematic Review
AI-powered evidence synthesis with documented search strategies
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Economics & Business use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Health Systems, Economic Evaluations, Quality of Life with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Economics, Econometrics and Finance researchers